Keyphrases
5-year Survival
33%
Adult Patients
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Bortezomib
50%
Cytogenetic Abnormalities
50%
Del17p
100%
High Risk
16%
In(III)
16%
Induction Regimen
50%
Latin America (LATAM)
16%
Latin American Populations
16%
Maintenance Therapy
50%
Median Progression-free Survival
16%
MM Patients
16%
Multiple Myeloma
16%
Multiple Myeloma Patients
100%
Multivariate Analysis
16%
Newly Diagnosed
33%
Newly Diagnosed multiple Myeloma
100%
Overall Survival
50%
Poor Prognosis
16%
Positive Impact
16%
Progression-free Survival
33%
Scarce Information
16%
Significant Benefit
16%
Survival Analysis
100%
Therapy Groups
16%
Transplant Eligibility
100%
Medicine and Dentistry
Autologous Stem Cell Transplantation
20%
Bortezomib
60%
Group Therapy
20%
Maintenance Therapy
60%
Multiple Myeloma
100%
Multivariate Analysis
20%
Overall Survival
100%
Progression Free Survival
60%
Survival Analysis
100%
Transplantation
100%
Immunology and Microbiology
Autologous Stem Cell Transplantation
20%
Multiple Myeloma
100%
Overall Survival
100%
Progression Free Survival
60%
Transplant Procedure
100%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
60%
Multiple Myeloma
100%
Overall Survival
100%
Progression Free Survival
60%
Biochemistry, Genetics and Molecular Biology
Autologous Stem Cell Transplantation
20%
Cytogenetics
60%
Multivariate Analysis
20%
Overall Survival
100%
Progression Free Survival
60%
Agricultural and Biological Sciences
Americans
33%
Autologous Stem Cell Transplantation
33%
Cytogenetics
100%
Multivariate Analysis
33%